NetworkNewsBreaks – TapImmune, Inc. (NASDAQ: TPIV) Receives Positive DSMB Safety Review for TPIV 200, Advances Phase 2 Trial
TapImmune (NASDAQ: TPIV) this morning said it has received a positive recommendation from an independent Data Safety Monitoring Board (DSMB) regarding the company’s lead cancer vaccine candidate, TPIV 200, to continue dosing triple-negative breast cancer (TNBC) patients in an ongoing phase 2 clinical trial. The planned safety review was conducted when enrollment was at 25 percent (20/80 patients). The four-arm trial is designed to test the safety, dosing level and optimal treatment regimen of TPIV 200 against TNBC cells. TapImmune will enroll the remaining patients at 12 clinical centers in the U.S., with enrollment completion targeted for the end of…







